tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

Evidence-based medicine

0

Caitlin Rothermel

Posted on March 7, 2013 by Patti Peeples, R.Ph., Ph.D.

What do you think?  Should PROs be included in composite endpoints along with more traditional clinical measures?  Read Cardiovascular Disease and Patient-reported Outcomes – Can Composite Endpoints Work? by Caitlin Rothermel and weigh in!

Guest Bloggers cardiovascular disease, clinical trials, composite endpoints, Evidence-based medicine, PROs

Post navigation

Newer Articles

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • The Emerging Outcomes Demonstration / Cost Management Challenge
  • Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression
  • Get to Know R-S-S (Regulatory Scientific and Health Solutions)
  • Will 2023 Be the Year AI Disrupts Healthcare?

HealthEconomics.Com Twitter Feed

HealthEconomics.Com | A Scientist.com Company Follow

www_healthecon
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
23 Mar

Cidara’s Anti-Fungal Receives Approval with Priority Review from US FDA

http://ow.ly/1eYG50NqwZR

#HEOR #Therapeutics #Pharma #Antifungal

Reply on Twitter 1639014196095635456 Retweet on Twitter 1639014196095635456 Like on Twitter 1639014196095635456 Twitter 1639014196095635456
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
23 Mar

Real-World Evidence Explores Inpatient and Outpatient Delivery of CAR T-Cell Therapy

http://ow.ly/nImB50NqwTr

#HEOR #RWE #Research #Oncology

Reply on Twitter 1638999106734673920 Retweet on Twitter 1638999106734673920 Like on Twitter 1638999106734673920 Twitter 1638999106734673920
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
23 Mar

Rare Skin Cancer Drug by Incyte Receives Accelerated Approval

http://ow.ly/eSLk50NqwO5

#HEOR #Therapeutics #Pharma #Oncology #RareDisease

Reply on Twitter 1638983995697545216 Retweet on Twitter 1638983995697545216 Like on Twitter 1638983995697545216 Twitter 1638983995697545216
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes